Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R L CECIL

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Organic Letters|October 12, 2002
Synthesis of cis-solamin using a permanganate-mediated oxidative cyclizationAlexander R L Cecil, Richard C D Brown
The Journal of Experimental Medicine|October 30, 2009
BACTERIOLOGY OF THE BLOOD AND JOINTS IN RHEUMATIC FEVERR L Cecil, E E Nicholls, W J Stainsby
The Journal of Organic Chemistry|May 11, 2004
Total synthesis and preliminary biological evaluation of cis-solamin isomersAlex R L Cecil, Yulai Hu, María J Vicent, et al.
Organic & Biomolecular Chemistry|March 25, 2006
Natural cis-solamin is a mixture of two tetra-epimeric diastereoisomers: biosynthetic implications for Annonaceous acetogeninsYulai Hu, Alex R L Cecil, Xavier Frank, et al.
Current Medicinal Chemistry|June 9, 2011
Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitorsS J Shuttleworth, F A Silva, A R L Cecil, et al.
Leukemia & Lymphoma|August 9, 2021
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphomaLoretta J Nastoupil, Sattva S Neelapu, Richard Eric Davis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid TumorsApostolia M Tsimberidou, Philip A Beer, Carrie A Cartwright, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Organic Letters|October 12, 2002
Synthesis of cis-solamin using a permanganate-mediated oxidative cyclizationAlexander R L Cecil, Richard C D Brown
The Journal of Experimental Medicine|October 30, 2009
BACTERIOLOGY OF THE BLOOD AND JOINTS IN RHEUMATIC FEVERR L Cecil, E E Nicholls, W J Stainsby
The Journal of Organic Chemistry|May 11, 2004
Total synthesis and preliminary biological evaluation of cis-solamin isomersAlex R L Cecil, Yulai Hu, María J Vicent, et al.
Organic & Biomolecular Chemistry|March 25, 2006
Natural cis-solamin is a mixture of two tetra-epimeric diastereoisomers: biosynthetic implications for Annonaceous acetogeninsYulai Hu, Alex R L Cecil, Xavier Frank, et al.
Current Medicinal Chemistry|June 9, 2011
Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitorsS J Shuttleworth, F A Silva, A R L Cecil, et al.
Leukemia & Lymphoma|August 9, 2021
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphomaLoretta J Nastoupil, Sattva S Neelapu, Richard Eric Davis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid TumorsApostolia M Tsimberidou, Philip A Beer, Carrie A Cartwright, et al.
Pageof 3